Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Loretta J. Nastoupil"'
Autor:
Miriam T. Jacobs, Michael D. Jain, Feng Gao, Loretta J. Nastoupil, Jay Y. Spiegel, Yi Lin, Saurabh Dahiya, Matthew Lunning, Lazaros Lekakis, Patrick M. Reagan, Olalekan O. Oluwole, Joseph McGuirk, Abhinav Deol, Alison Sehgal, Andre Goy, Brian T. Hill, Charalambos Andreadis, Javier Munoz, Julio C. Chavez, N. Nora Bennani, Aaron P. Rapoport, Julie M. Vose, David B. Miklos, Sattva S. Neelapu, Armin Ghobadi, Frederick L. Locke
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:753-759
The majority of patients with large B-cell lymphoma treated with axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, develop cytokine release syndrome (CRS). Whether the lack of development of CRS with axi-
Autor:
Peter A. Riedell, Wei-Ting Hwang, Loretta J. Nastoupil, Martina Pennisi, Joseph P. McGuirk, Richard T. Maziarz, Veronika Bachanova, Olalekan O. Oluwole, Jamie Brower, Oscar A. Flores, Nausheen Ahmed, Levanto Schachter, Kharmen Bharucha, Bhagirathbhai R. Dholaria, Stephen J. Schuster, Miguel-Angel Perales, Michael R. Bishop, David L. Porter
Publikováno v:
Transplantation and Cellular Therapy. 28:669-676
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-directed chimeric antigen receptor (CAR) T cell therapies approved for the treatment of relapsed/refractory aggressive B cell lymphomas. We present a multicenter retrospective
Autor:
Hua‐Jay J. Cherng, Guofan Xu, Lei Feng, Raphael Steiner, Luis Fayad, Paolo Strati, Ranjit Nair, Loretta J. Nastoupil, Hun Ju Lee, Sattva S. Neelapu, Christopher R. Flowers, Maria Rodriguez, Michael Wang, Fredrick Hagemeister, Chelsea C. Pinnix, Jeremy Ramdial, Samer Srour, Yago Nieto, Katayoun Rezvani, Richard Champlin, Partow Kebriaei, Jason Westin, Homer A. Macapinlac, Elizabeth Shpall, Sairah Ahmed
Publikováno v:
British Journal of Haematology. 200:35-44
Salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT) is a potentially curative treatment for patients with relapsed or refractory large B-cell lymphoma (rrLBCL) with chemosensitive disease. A
Autor:
Efstratios Koutroumpakis, Raphael E Steiner, Sairah Ahmed, Michael Wang, Loretta J. Nastoupil, Nicolas Palaskas, Catherine M. Claussen, Jason R. Westin, Paolo Strati, Anita Deswal, Chelsea C. Pinnix, Jose Banchs, Lei Feng, Elizabeth J. Shpall, Francisco Vega, Cristina Gutierrez, Kaveh Karimzad, Sattva S. Neelapu, Gabriela Rondon, Melody R. Becnel
Publikováno v:
Haematologica. 107:1555-1566
Standard of care (SOC) chimeric antigen receptor (CAR) T-cell therapies such as axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are associated with multisystem toxicities. There is limited information available about cardiovascular
Autor:
Joseph D. Khoury, Sarah A. Milgrom, Loretta J. Nastoupil, Elizabeth J. Shpall, Jillian R. Gunther, Sattva S. Neelapu, Sairah Ahmed, Raphael E Steiner, Maria Gule-Monroe, Ranjit Nair, Karine A. Al Feghali, Jason R. Westin, Chelsea C. Pinnix, Chitra Hosing, Nathan Fowler, Tommy Sheu, Penny Fang, Bouthaina S. Dabaja, Christopher R. Flowers, Paolo Strati, Yago Nieto
Publikováno v:
Leukemia & Lymphoma. 62:2400-2407
This study aimed to assess the prognostic value of baseline disease distribution for patients with the secondary central nervous system (CNS) diffuse large B-cell lymphoma (DLBCL) treated with chemotherapy and radiation (RT). 44 patients with seconda
Autor:
Paolo Strati, Andrew P. Jallouk, Ryan Sun, Jaihee Choi, Kaberi Das, Hua-Jay Cherng, Sairah Ahmed, Hun J. Lee, Swaminathan P. Iyer, Ranjit Nair, Loretta J. Nastoupil, Raphael E. Steiner, Chad D. Huff, Yao Yu, Haleigh Mistry, Brittany Pulsifer, Mansoor Noorani, Neeraj Saini, Elizabeth J. Shpall, Partow Kebriaei, Christopher R. Flowers, Jason R. Westin, Michelle A. T. Hildebrandt, Sattva S. Neelapu
Publikováno v:
Leukemia
Conditioning chemotherapy (CCT) has been shown to be essential for optimal efficacy of chimeric antigen receptor (CAR) T-cell therapy. Here, we determined whether the change in absolute lymphocyte count, referred to as delta lymphocyte index (DLIx),
Autor:
Abhinav Deol, Amanda F. Cashen, N. Nora Bennani, Khoan Vu, Michael D. Jain, David B. Miklos, Sattva S. Neelapu, Brian T. Hill, Jason R. Westin, Julie M. Vose, Alison R. Sehgal, Julio C. Chavez, Aaron P. Rapoport, Lazaros J. Lekakis, Andre Goy, Patrick M. Reagan, Javier Munoz, Joseph P. McGuirk, Loretta J. Nastoupil, Lei Feng, Olalekan O. Oluwole, Saurabh Dahiya, Jay Y. Spiegel, Frederick L. Locke, Charalambos Andreadis, Yi Lin, Matthew A. Lunning, Armin Ghobadi
Publikováno v:
J Clin Oncol
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 27
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 27
PURPOSE Axicabtagene ciloleucel (axi-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory large B-cell lymphoma (LBCL) on the basis of the single-arm phase II ZUMA-1 trial, which showed b
Autor:
Ajlan Al Zaki, Lei Feng, Grace Watson, Sairah A. Ahmed, Haleigh Mistry, Loretta J. Nastoupil, Misha Hawkins, Ranjit Nair, Swaminathan P. Iyer, Hun J. Lee, Raphael E. Steiner, Christopher R. Flowers, Elizabeth J. Shpall, Partow Kebriaei, Sattva S. Neelapu, Jason R. Westin, Paolo Strati
Publikováno v:
Blood advances. 6(9)
About 70% of patients with large B-cell lymphoma (LBCL) who are treated with axicabtagene ciloleucel (axi-cel) and who achieve a partial response (PR) or stable disease (SD) on the day 30 (D30) positron emission tomography (PET)–computed tomography
Autor:
Paolo Strati, Sandra B. Horowitz, Luis Fayad, Hun J. Lee, Victor E. Mulanovich, Swapna Johncy, Sairah Ahmed, Sherry Adkins, Ankur Varma, Felipe Samaniego, Nathan Fowler, Sara Arafat, Jason R. Westin, Loretta J. Nastoupil, Ella Ariza Heredia, Fredrick B. Hagemeister, Yiming Chen, Sattva S. Neelapu, Partow Kebriaei
Publikováno v:
Haematologica
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 may be associated with long-term adverse effects such as cytopenia and immune deficiency. In order to characterize these late events, we analyzed 31 patients with relapsed or refractory la
Autor:
Sattva S. Neelapu, Maria Alma Rodriguez, Jason R. Westin, Hubert H. Chuang, Ranjit Nair, Luis Fayad, Raphael E Steiner, Fredrick B. Hagemeister, Hua Jay J. Cherng, Homer A. Macapinlac, Christopher R. Flowers, Loretta J. Nastoupil, Paolo Strati, Hun Ju Lee, Lei Feng, Felipe Samaniego
Publikováno v:
Leuk Lymphoma
Many patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) will not respond to platinum-containing salvage chemotherapy. Predicting treatment failure earlier could help clinicians minimize chemotherapy toxicities for non-responde